Written Testimony Presented Before the
House Committee on Health and
House Committee on Higher Education

March 18, 2008 at 2:15 p.m.

by
Virginia S. Hinshaw, Chancellor
and
Carl-Wilhelm Vogel, MD, PhD
Director, Cancer Research Center of Hawai‘i
University of Hawai‘i at Mānoa

SB 2040 SD1—RELATING TO CANCER SURVEILLANCE

Chair Representative Josh Green, Vice Chair Representative John Mizuno, Members of the
House Committee on Health;
Chair Representative Jerry L. Chang, Vice Chair Representative Joe Bertram, Members of the
House Committee on Higher Education:

The University of Hawaii strongly supports S.B. No. 2040, SD1 Relating to Cancer Surveillance,
which would help us to achieve the goals of Hawaii Comprehensive Cancer Control Consortium
(HCCCC), namely to save lives and improve the quality of life for individuals affected by
cancer. First, the revised statute would give Hawaii citizens the right to choose whether or not
they wish to participate in cancer research studies. Presently, physician permission is required in
Hawaii before individual contact can be made. The requirement for physician permission
preempts our citizen’s ability to make personal decisions about their healthcare and limits their
accrual to beneficial cancer research.

The second obstacle to achieving the goals of the HCCCC Plan is the ambiguous meaning of
‘data or relevant material’ that is part of the statute. The Hawaii Tumor Registry currently
collects tissue and other biological specimens from cancer patients as part of its activities. It is
important that the statute be clarified in this regard, providing the Tumor Registry with the
authority to collect and house biological specimens that might be used in de-
identified/anonymized research.

Finally, although information on pre-cancerous lesions has been collected by the HTR in the past
(e.g., cervical dysplasia), specific statutory authority to do so is unclear. Collection of
information on individuals with pre-cancerous disease is an important means to monitor cancer
screening activities (e.g., prostate cancer screening) or to monitor the efficacy of cancer
vaccines, such as the newly introduced vaccine against the human papillomavirus.

We therefore advocate these minor revisions to H.R.S. § 324-21 and 321-29 to 1) increase
community participation in research studies; 2) increase the research utility of the Hawaii Tumor
Registry; 3) allow comprehensive monitoring of the efficacy of cancer screening and cancer vaccination activities; 4) enhance the quality of life of cancer survivors; and 5) stimulate community awareness of the Cancer Information Service and local community cancer prevention efforts. We urge the Committee to pass S.B. No. 2040, SD1. Thank you for this opportunity to testify.